The determination of size as well as power of a test is a vital part of a Clinical Trial Design. This research focuses on the simulation of clinical trial data with time-to-event as the primary outcome. It investigates the impact of different recruitment patterns, and time dependent hazard structures on size and power of the log-rank test. A non-homogeneous Poisson process is used to simulate entry times according to the different accrual patterns. A Weibull distribution is employed to simulate survival times according to the different hazard structures. The current study utilizes simulation methods to evaluate the effect of different recruitment patterns on size and power estimates of the log-rank test. The size of the log-rank test is est...
A challenge arising in cancer immunotherapy trial design is the presence of non-proportional hazards...
Background Sample size calculation is a key point in the design of a randomized controlled trial. Wi...
Background: A common feature of many recent trials evaluating the effects of immunotherapy on surviv...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
In many pharmaceutical studies, non-inferiority clinical trials are usually conducted because of the...
This paper evaluates the loss of power of the simple and stratified logrank tests due to heterogenei...
Survival analysis concerns the characterization or comparison of one or more distributions of the ti...
Sizes and power of selected two-sample tests of the equality of survival distributions are compared ...
Group sequential design has been widely applied in clinical trials in the past few decades. The samp...
In clinical trials with time-to-event endpoints, it is not uncommon to see a significant pro...
Group sequential design has been widely applied in clinical trials in the past few decades. The samp...
When designing a cancer clinical trial, it is usual to assume an exponential distribution for a time...
An approach to trial design and analysis in the era of non-proportional hazards of the treatment eff...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Nonproportional hazards (NPH) have been observed in confirmatory clinical trials with time to event ...
A challenge arising in cancer immunotherapy trial design is the presence of non-proportional hazards...
Background Sample size calculation is a key point in the design of a randomized controlled trial. Wi...
Background: A common feature of many recent trials evaluating the effects of immunotherapy on surviv...
The determination of size as well as power of a test is a vital part of a Clinical Trial Design. Thi...
In many pharmaceutical studies, non-inferiority clinical trials are usually conducted because of the...
This paper evaluates the loss of power of the simple and stratified logrank tests due to heterogenei...
Survival analysis concerns the characterization or comparison of one or more distributions of the ti...
Sizes and power of selected two-sample tests of the equality of survival distributions are compared ...
Group sequential design has been widely applied in clinical trials in the past few decades. The samp...
In clinical trials with time-to-event endpoints, it is not uncommon to see a significant pro...
Group sequential design has been widely applied in clinical trials in the past few decades. The samp...
When designing a cancer clinical trial, it is usual to assume an exponential distribution for a time...
An approach to trial design and analysis in the era of non-proportional hazards of the treatment eff...
AbstractThe semi-parametric proportional hazards model is widely adopted in randomized clinical tria...
Nonproportional hazards (NPH) have been observed in confirmatory clinical trials with time to event ...
A challenge arising in cancer immunotherapy trial design is the presence of non-proportional hazards...
Background Sample size calculation is a key point in the design of a randomized controlled trial. Wi...
Background: A common feature of many recent trials evaluating the effects of immunotherapy on surviv...